Full Press Release Details
Pliant Therapeutics Reports Positive Interim Results from
Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
- Single dose administration of PLN-74809 achieved v 6 target engagement
up to 98% in the lungs of IPF patients
- All doses achieved target engagement above the threshold
for predicted anti-fibrotic activity, with an observed dose-response relationship
- PLN-74809 reached highly fibrotic regions of the lung and was bound to v 6 in IPF patients
- Data provide insight into potential anti-fibrotic activity of PLN-74809 at the doses being evaluated
in the ongoing Phase 2a INTEGRIS-IPF trial
- Company to host conference call and webcast today at 8:00 a.m. ET
SOUTH SAN FRANCISCO, CA- September 7, 2021 Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical
stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced positive interim results from a Phase 2a positron emission tomography (PET) imaging-based clinical trial of PLN-74809, an oral small molecule dual selective inhibitor of v 6/ v 1, in patients with idiopathic
pulmonary fibrosis (IPF). Across four dose levels, all patients achieved greater than 50% target engagement after a single dose of PLN-74809. Target engagement of 50% was previously established in a Phase 1b
trial as the threshold for predicted clinical anti-fibrotic effect. In addition, there was a dose- and plasma concentration-dependent response with the two highest doses approaching target saturation.
We believe the high target engagement levels seen after the administration of just a single dose illustrate the potential of PLN-74809 to show a potent anti-fibrotic effect in our longer-term clinical trials, said ric Lefebvre, M.D., Chief Medical Officer of Pliant Therapeutics. Furthermore, these data represent a
significant step forward in our understanding of the potential anti-fibrotic activity of PLN-74809 and support the selected doses in our ongoing 12-week Phase 2a INTEGRIS-IPF trial.
The ongoing Phase 2a open-label PET imaging clinical trial is designed to evaluate v 6 target engagement levels achieved by PLN-74809 when
administered across single-doses of 60 mg, 120 mg, 240 mg or 320 mg in IPF patients. The trial is also evaluating safety, tolerability and pharmacokinetics. Patients undergo a PET scan prior to dosing and at four hours post-dose to evaluate target
v 6 specific engagement. Images are analyzed for regions of high fibrotic activity,
which are then evaluated for target engagement. Following completion of a standard washout period, patients may consent to receive a second dose of PLN-74809 at a different dose level followed by a second
As fibrosis is a chronic disease, proof-of-efficacy
in human trials is expensive and takes years to complete. Pliant utilizes pharmacodynamic biomarkers and advanced imaging techniques, including PET, to evaluate target engagement by our product candidates over relatively short time periods and de-risk Pliant s programs by designing clinical trials that allow the Company to show proof-of-mechanism in advance of clinical
Interim Phase 2a PET Clinical Trial Results
Four IPF patients were administered six single doses of PLN-74809 across 60 mg, 120 mg, 240 mg or 320 mg, generating a
total of six post-dose scans.
PLN-74809 Demonstrated Lung Penetration, with Greater than 50% Target Engagement
Achieved in the Lungs of All IPF Patients Across All Dose Cohorts
Dose and Plasma Concentration Response Established
PLN-74809 Well-Tolerated Across All Doses
Conference Call and Webcast
conference call and webcast today at 8:00 a.m. ET to discuss this update. The webcast will be available in the Events & Presentations section of Pliant s website. This update can also be accessed by dialing (833) 519-1340 (United States and Canada) or (914) 800-3902 (international) and providing the passcode 6186023. An archived reply of the webcast will be available on Pliant s
website for 90 days following the event.
About Pliant Therapeutics, Inc.
Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrotic and related diseases.
Pliant s lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of v 6 and v 1 integrins that is in development for the treatment of idiopathic
pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently
recruiting for Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of
v 1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will,
expect, anticipate, estimate, intend, and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking
statements. These statements include those regarding the pharmacodynamics and therapeutic potential of PLN-74809, our plans for the future development of PLN-74809, the
potential of our Phase 2a PET trial to predict future clinical outcomes and the potential for the preliminary results of this trial to predict future results. Because such statements deal with future events and are based on our current expectations,
they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking
statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the ongoing nature of our
Phase 2a PET trial and the possibility that the preliminary data will not be predictive of full data from this trial, the possibility that results from this trial will not be predictive of future clinical outcomes, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development,
our capital requirements and the need for additional financing, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled Risk
Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K filed with the SEC on March 16, 2021, as updated
by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, each available on the SEC s website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of
the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events, or otherwise.
Investor and Media Contact:
Vice President, Investor Relations and
Corporate Communications
Pliant Therapeutics, Inc.